Slide 1: Transforming Early Cardiac Diagnostics: Acarix Q2 2026
Transforming Early Cardiac Diagnostics Acarix Q2 2026 Aamir Mahmood President & CEO 08/13/2026
Slide 2: The CADScor System: Transforming Early Cardiac Diagnostics with Rapid Assessment
The CADScor®System Transforming Early Cardiac Diagnostics with Rapid Assessment A rapid, point of care diagnostic aid that uses highly sensitive acoustics and advanced computational processing to calculate a patient specific CAD risk score Quickly and easily risk-stratify significant coronary artery
Slide 3: United Arab Emirates Regulatory Approval
United Arab Emirates Regulatory Approval Acarix Enters the Gulf Region About the Approval On August 10, 2026, Acarix received regulatory approval for the CADScor® System from the Emirates Drug Establishment (EDE) and the Ministry of Health and Prevention (MOHAP), clearing the way for commercial avai
Slide 4: Executive Summary
q | Executive Summary
Slide 5: US Market Drives Strong Growth in Q2 2026
US Market Drives Strong Growth in Q2 2026 Total revenue and US commercial activity accelerated in Q2 2026 compared to the same period last year ● Delivered 29 CADScor® Systems, a 53% increase ● Total revenue up 102% to SEK 2,308 thousand ● US revenue up 212% to SEK 1,857 thousand US patch sales doub
Slide 6: CEO Aamir Mahmood commentary
The second quarter of 2026 was another period of strong commercial progress for Acarix, with total revenue more than doubling to SEK 2,308 thousand. The United States remains the primary engine of our growth. We delivered 29 CADScor® Systems, a 53% increase, and US patch sales doubled year-over-year
Slide 7: Q2 Highlights
Q2 Highlights q |
Slide 8: ACC.26 Presentation Validates Clinical & Commercial Case
ACC.26 Presentation Validates Clinical & Commercial Case About the Presentation Acarix presented its abstract at ACC.26, the American College of Cardiology’s 2026 annual scientific session, highlighting the diagnostic utility of the CADScor® System in comparison to standard stress tests for chest pai
Slide 9: Creating a Scalable Pathway for Reimbursement
Creating a Scalable Pathway for Reimbursement ● Completed successful enrollment of US Performance Study and completing data review ● Pending submission and publication to submit for CPT I Classification ● Scheduling meeting with CMS for review of CADScor under the HOPPS (Hospital Outpatient Prospecti
Slide 10: Q2 Financials
Tq acarix? Q2 Financials
Slide 11: Q2 2026 Financial Highlights
Q2 2026 Financial Highlights Total Systems US Revenue Revenue 212% Delivered 102% 53% YoY Quarterly YoY Quarterly YoY Quarterly The second quarter of 2026 delivered accelerating US growth, with total revenue more than doubling year-over-year. Disciplined cost control drove a 26% improvement in net l
Slide 12: Q2 Total Revenue Growth
Q2 Total Revenue Growth Sales kSEK 2,308 +102% 1,140 Q2 2025 Q2 2026 Currency-adjusted revenue increased 108% overall and 223% in the US, reinforcing sustained commercial momentum. 12
Slide 13: U.S. CADScor System Installations Driving Recurring Patch Sales
U.S. CADScor® System Installations Driving Recurring Patch Sales U.S. CADScor System Installations U.S. Acoustic Patch Sales 13
Slide 14: Expanding U.S. Clinical Adoption Across Key Disciplines
Expanding U.S. Clinical Adoption Across Key Disciplines U.S. CADScor System Installations* Broad-Based Growth Across Care Settings Quarterly growth continued across all care settings, led by strong expansion in Primary Care. Cardiology remained a significant contributor, while Concierge Medicine main
Slide 15: Q2 U.S. Patch Sales
Q2 U.S. Patch Sales Boxes (1 box = 20 patches) 140 +100% 70 Q2 2025 Q2 2026 US patch sales doubled year-over-year in Q2 2026. Clinicians are incorporating the CADScor System into routine practice, driving a growing recurring-revenue base from the installed system fleet. 15
Slide 16: Q2 Global Gross Margin
Q2 Global Gross Margin Gross Margin 94% 84% Q2 2025 Q2 2026 Gross margin was 84% in Q2 2026, compared with 93% a year earlier. The lower margin reflects a shift in sales mix toward CADScor® System deliveries this quarter, alongside continued patch sales. 16
Slide 17: Q2 Operating Cost Reduction
Q2 Operating Cost Reduction OPEX kSEK 13,915 11,256 -19% Q2 2025 Q2 2026 Operating costs fell 19% to SEK 11,256 thousand from SEK 13,915 thousand in Q2 2025, reflecting continued cost-efficiency initiatives and stronger operational leverage. 17
Slide 18: Q2 Net Loss
Q2 Net Loss Net Loss kSEK -12,863 -9,482 26% Q2 2025 Q2 2026 Net loss improved 26% to SEK –9,482 thousand from SEK –12,863 thousand in Q2 2025, reflecting disciplined execution alongside continued commercial growth. 18
Slide 19: Q2 Monthly Burn Rate
Q2 Monthly Burn Rate Monthly Burn Rate kSEK -4,200 -3,100 -26.2% Q2 2025 Q2 2026 Average monthly operating cash burn improved to SEK –3,100 thousand from SEK –4,200 thousand in Q2 2025, reflecting tighter cost control and more efficient working-capital management. 19
Slide 20: Financing Update – Q2 2026
Financing Update – Q2 2026 ● At the start of Q4 2025: the Board approved a directed share issue to U.S. and Nordic investors, with an expected gross raise of approximately SEK 33.4 million before issuance costs. ● By June 30, 2026: the full amount had been received into the company’s share issue acc
Slide 21: Significant Opportunities Ahead
Significant Opportunities Ahead Acarix is positioned to convert commercial momentum into durable, recurring growth in H2 2026 and beyond. Expanding Reimbursement 29 Systems Delivered This Continued Double-Digit US Coverage Quarter Growth Deeper clinical adoption is the key driver of sustainable, recu
Slide 22: Thank You
Transforming Early Cardiac Diagnostics Thank You 22